Looking for the latest in oncology clinical literature? You've found the right page. MDLinx Oncology medical editors comb through the top peer-reviewed clinical journals for the articles they think will make a difference to you and your practice. You'll find them organized here by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants and the whole cancer care team can stay current on the literature as it is published.
On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We feature clinical pearls as well, from The Smartest Oncologist to oncology topics in The Smartest Pediatrician daily quiz challenges.
Your Unread Messages in Oncology
See All >> Messages include industry-sponsored communications and special communications from MDLinx
Patients 50+ may be at increased risk for pneumococcal disease. Learn what you can do.
Smartest Doc Challenge
MDLinx
Pediatric Oncology Clinical Pearls
D Scott Cunningham MD, PhD
Site Editor, MDLinx
Transition rates for adenomas to CRC
Jill Baker
MDLinx Career Center
New Jobs in Your Specialty
MDLinx Top Read
MDLinx
Are your journals collecting cobwebs?
MDLinx Conference Center
MDLinx
June Conference Calendar
1 Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial The Lancet Oncology, June 18, 2013 Clinical Article
2 Post-diagnosis cruciferous vegetable consumption and breast cancer outcomes: A report from the After Breast Cancer Pooling Project Cancer Epidemiology, Biomarkers & Prevention, June 18, 2013
3 ID3 contributes to cerebrospinal fluid seeding and poor prognosis in medulloblastoma Full Text BMC Cancer, June 18, 2013
4 High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients Full Text BMC Cancer, June 18, 2013
5 Evaluating the expression of CARMA3 as a prognostic tumor marker in renal cell carcinoma Tumor Biology, June 18, 2013
6 Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer Cancer Epidemiology, June 18, 2013
7 Molecular subtypes of ductal carcinoma in situ in African American and Caucasian American Women: Distribution and correlation with pathological features and outcome Cancer Epidemiology, June 18, 2013
8 Effects of polymorphisms in alcohol metabolism and oxidative stress genes on survival from head and neck cancer Cancer Epidemiology, June 18, 2013
9 Colonoscopic surveillance of first-degree relatives of colorectal cancer patients in a faecal occult blood screening programme Cancer Epidemiology, June 18, 2013
10 A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer International Journal of Clinical Oncology, June 18, 2013
11 Meat-Related Mutagens and Pancreatic Cancer: Null Results from a Clinic-Based Case–Control Study Cancer Epidemiology, Biomarkers & Prevention, June 18, 2013 Clinical Article
12 Herbal medicine and acupuncture for breast cancer palliative care and adjuvant therapy Full Text Evidence-based Complementary and Alternative Medicine , June 18, 2013 Review Article
13 Physical Activity and Risk of Lymphoma: A Meta-Analysis Cancer Epidemiology, Biomarkers & Prevention, June 18, 2013 Evidence Based Medicine Clinical Article
14 Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study Journal of Clinical Gastroenterology, June 18, 2013 Clinical Article
15 Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study Cancer Chemotherapy and Pharmacology, June 18, 2013 Clinical Article
16 A notch3 transcriptional module induces cell motility in neuroblastoma Clinical Cancer Research, June 18, 2013 Clinical Article
17 High prevalence of brca1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions Clinical Cancer Research, June 18, 2013 Clinical Article
18 Use of multiple endpoints and approval paths depicts a decade of fda oncology drug approvals Clinical Cancer Research, June 18, 2013 Review Article
19 Subsequent brain tumors in patients with autoimmune disease Neuro-Oncology, June 18, 2013 Clinical Article
20 Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming Cancer Cell, June 18, 2013 Clinical Article
As reported in the Journal of Pathology, the expression of vascular endothelial growth factor receptor (VEGFR)-1 is elevated in invasive hepatocellular cancer (HCC) specimens. In a study based on 135 HCC specimens, elevated VEGFR-1 was also associated with worse recurrence-free and overall survival.
Read the article summaryAs reported in Cancer, researchers from the NCI have reported that patients with AIDS have a 4-fold increased risk of HCC compared to the general population. The study findings were based on 615,150 patients with AIDS between 1980 and 2009. The risk for HCC in patients with AIDS was essentially the same during the monotherapy/dual therapy and highly active anti-retroviral therapy eras.
Read the article summaryAs reported in the International Journal of Cancer Research and Treatment, the pre-operative level of RAB25 is a predictor of disease-free survival (HR=18.2) and overall survival (HR=33.6) in patients with ovarian cancer. The study involved 36 and 16 women with ovarian cancer and benign tumors, respectively. The pre-operative cell-free DNA of genes (B2M, RAB25, CLDN4, and ABCF2) were measured and RAB25 was shown to be an independent prognostic factor.
Read the article summary1 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology, April 15, 2013
2 Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer: a randomized biomarker pilot study Clinical Cancer Research, May 6, 2013
3 Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer Journal of the National Cancer Institute, May 1, 2013
4 Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma Annals of Oncology, May 6, 2013
5 Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles The Lancet, April 23, 2013
6 Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial The Lancet Oncology, May 17, 2013
7 Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial The Lancet Oncology, May 3, 2013
8 Association of metformin use with cancer incidence and mortality: A meta-analysis Cancer Epidemiology, April 22, 2013 Review Article
9 Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial European Journal of Cancer, April 2, 2013
10 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, May 3, 2013
11 Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors Cancer, April 12, 2013
12 Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA Trial Journal of Clinical Oncology, April 25, 2013
13 Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study The Lancet Oncology, May 3, 2013
14 AVEREL: A randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer Journal of Clinical Oncology, April 15, 2013
15 Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Childrens Research Hospital experience Cancer, May 2, 2013
16 Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial analysis Journal of Clinical Oncology, April 30, 2013
17 Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer British Journal of Cancer, May 7, 2013
18 Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis Journal of the National Cancer Institute, April 19, 2013 Evidence Based Medicine
19 Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study Journal of Clinical Oncology, April 29, 2013
20 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, April 23, 2013
Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncology more
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close